Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People's Republic of China.
Int J Nanomedicine. 2024 Aug 21;19:8519-8540. doi: 10.2147/IJN.S459960. eCollection 2024.
The effective accumulation of nanoparticles (NPs) in the tumour area is an important goals of current nanotechnology research, and a targeted nanoplatform is an effective solution. So we designed a multifunctional sound-sensitive targeted NP that combines a sonosensitizer to enable precisely targeted, deep-penetration sonodynamic therapy (SDT) in combination with multimodal imaging for the diagnosis and monitoring of renal cell carcinoma (RCC).
ZnPP@PP NPs (ZnPP@PLGA- PFP NPs) were prepared via a double emulsion method, and G250 was covalently attached to the NPs shell via the carbon diimide method. Physicochemical property tests were conducted on the ZnPP@G-PP NPs, including tests of particle size, potential distribution, encapsulation efficiency and drug loading capability. We assessed the targeting ability, the production of reactive oxygen species (ROS) and permeability of the NPs in vitro. Moreover, we evaluated the nanoparticle's multimodal imaging capabilities and therapeutic ability against RCC, both in vitro and in vivo.
The Znpp@G-PP NPs were successfully constructed, and their general properties showed uniform particle size, negative potential and good stability. The nanoparticles were successfully loaded with ZnPP and connected with G250, showing tumor-specific targeting ability. Under LIFU irradiation, the nanoparticles produced O by SDT. For RCC, PA/US multi-modal imaging of Znpp@G-PP NPs provide diagnostic information and monitor therapies in real time in 786-O RCC xenografts, with good biocompatibility. With the UTMD, nanoparticles can be effectively targeted into the tumor cells and penetrate into the tumor interior, significantly improving the SDT effect. Experiments in vitro and in vivo showed that the combination of the nanoparticles and LIFU could suppress the tumor, and the therapeutic effect was confirmed by immunohistochemistry.
ZnPP@G-PP NPs provide a promising theranostic strategy for RCC and a platform for further research on improving the efficacy of diagnosis and treatment.
有效将纳米颗粒(NPs)积聚在肿瘤区域是当前纳米技术研究的重要目标,而靶向纳米平台是一种有效的解决方案。因此,我们设计了一种多功能声敏靶向 NP,它结合了声敏剂,可实现精确靶向、深层穿透声动力学疗法(SDT),并结合多模态成像用于诊断和监测肾细胞癌(RCC)。
通过双重乳液法制备了 ZnPP@PP NPs(ZnPP@PLGA-PFP NPs),并通过碳二亚胺法将 G250 共价连接到 NPs 壳上。对 ZnPP@G-PP NPs 进行了理化性质测试,包括粒径、电位分布、包封效率和载药能力测试。我们评估了 NPs 的体外靶向能力、活性氧(ROS)产生能力和通透性。此外,我们评估了纳米颗粒的多模态成像能力和对 RCC 的治疗能力,包括体外和体内。
成功构建了 Znpp@G-PP NPs,其一般性质表现为均匀的粒径、负电位和良好的稳定性。纳米颗粒成功负载了 ZnPP 并与 G250 连接,表现出肿瘤特异性靶向能力。在 LIFU 照射下,纳米颗粒通过 SDT 产生 O。对于 RCC,Znpp@G-PP NPs 的 PA/US 多模态成像可在 786-O RCC 异种移植瘤中提供诊断信息并实时监测治疗,具有良好的生物相容性。通过 UTMD,纳米颗粒可以有效地靶向肿瘤细胞并穿透肿瘤内部,显著提高 SDT 效果。体外和体内实验表明,纳米颗粒与 LIFU 的结合可以抑制肿瘤,免疫组织化学证实了治疗效果。
ZnPP@G-PP NPs 为 RCC 提供了一种有前途的治疗策略和一种用于提高诊断和治疗效果的研究平台。